Lancet 388 , 20232038 (2016)
Q3: What dose ranges appear in IGF-1 LR3 research protocols
FOXO4-DRI Potential Selectivity As mentioned, FOXO4-DRI is believed to selectively disrupt the binding of FOXO4 to p53, which may lead to the activation of p53, which in turn may stimulate the process of removing senescent cells
Clinical and experimental studies determine significant reductions in markers of gastrointestinal inflammation, such as CRP and TNF-, following IF interventions, suggesting its role in attenuating systemic and local inflammation [82, 83]
Most patients notice results within a few days
It cannot establish a safe or effective human outcome